ImmunityBio

NantKwest, Inc. is a clinical-stage immunotherapy company based in San Diego, California, focused on developing innovative treatments for cancer and viral infectious diseases. The company utilizes natural killer (NK) cells, a crucial component of the immune system, to create various immunotherapeutic agents, including activated NK cells and high-affinity NK cell product candidates. These therapies target virally-induced cancers and serious infections, such as those caused by the human papillomavirus and Ebola. NantKwest is also advancing its pipeline with specialized product candidates designed to treat solid tumors. The company has established collaborations with several organizations, including Altor BioScience and Be The Match BioTherapies, to enhance its therapeutic offerings and explore new applications, such as COVID-19 treatment leveraging newborn stem cells. Founded in 2002, NantKwest was previously known as Conkwest, Inc. and rebranded in 2015.

Altor BioScience Corporation is a biopharmaceutical company based in Miramar, Florida, specializing in the discovery, development, and commercialization of immunotherapeutic agents aimed at treating cancer, viral infections, and autoimmune diseases. Founded in 2002, the company focuses on the immunostimulatory properties of cytokines such as IL-15 and IL-2, which enhance the activation and proliferation of immune cells critical for combating malignancies and infections. Altor's product portfolio includes several candidates in various stages of development, such as ALT-801, a T-cell receptor-targeted therapy for cancer, and ALT-803, an IL-15 superagonist for solid tumors. Additionally, the company offers STAR Fusion and STAR Multimer Reagents for diagnosing and targeting cancer and viral infections, as well as tools for the detection of disease targets on cell surfaces. Altor BioScience aims to leverage its innovative technologies to advance treatment options for patients with challenging health conditions.

VivaBioCell is a biotechnology company focused on developing innovative products through proprietary technologies in cell culture and tissue engineering. The company addresses unmet medical needs, particularly in the early diagnosis of autoimmune diseases, such as scleroderma and graft versus host disease, as well as the treatment of oro-dental and maxillo-facial defects. VivaBioCell leverages its existing technologies while also pursuing the development of new innovations. The company collaborates with recognized academic research centers, particularly in Italy, to identify new opportunities. Furthermore, VivaBioCell has created automated cell expansion systems that enhance the manufacturing processes for sustainable cell therapies, ensuring compliance with current Good Manufacturing Practices (cGMP), scalability, and cost efficiency. This automation allows for a transition from manual protocols to more efficient and scalable production methods in the healthcare sector.